Advanced Lung Cancer, Advanced Malignant Solid Tumor, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Conditions
Brief summary
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.
Interventions
DRUGBT02
monoclonal antibody injection with intravenous administration every 2 or 3 weeks
Sponsors
Biotroy Therapeutics
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with pathologically confirmed locally advanced/unresectable or metastatic or recurrent non-small cell lung cancer (NSCLC, according to AJCC TNM staging) and advanced/unresectable limited-stage or extensive-stage small cell lung cancer (SCLC, according to VALG combined with AJCC TNM staging)，who have failed in the prior systemic therapy . 2. Adequate organ and hematologic function. 3. At least 1 extracranial measurable lesion. 4. An ECOG activity status score of 0-1. 5. A life expectancy of ≥ 3 months. 6. Eligible participants of childbearing potential (both males and females) must agree to using effective contraception throughout the study period. 7. Good compliance and willingness to follow up.
Exclusion criteria
1. Patients with sensitive mutations or gene fusions related to lung cancer. 2. Prior to the first dose , received systemic antitumor therapy, scheduled major surgical procedure within 4 weeks, received systemic immunostimulants within 5 half-lives and systemic corticosteroids or other immunosuppressive medications within 14 days. 3. A history of active autoimmune disease within the past 2 years. 4. A history of clinically significant cardiovascular disease, severe cardiac rhythm /conduction abnormalities or LVEF \<50% . A history of severe pulmonary disease that may lead to severe episodes of dyspnea. 5. A severe acute or chronic infection when enrollment. 6. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 . 7. Unresolved \> Grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known hypersensitivity to the formulation of the investigational product. 8. Clinically active CNS metastases or meningeal metastases. 9. A history of other type of malignancies. 10. Received a live attenuated vaccine within 28 days prior to the administration of the investigational product. 11. Poor compliance. 12. A history of alcohol or drugs abuse. 13. Current pregnancy or breastfeeding. 14. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | through study completion, an average of 2 years |
| Dose limited toxicity incidence | Through the dose escalation phase , an average of 8 months |
| Maximum tolerated dose(MTD) | Through the dose escalation phase, an average of 8 months |
| Recommended Phase II dose (RP2D) | Through study completion, an average of 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate (DCR) on tumor assessments | Through the study completion, an average of 2 years |
| Mean and median Area under the curve (AUC) of BT02 following first dose and repeated administration at each dose level | Through study completion, an average of 2 years |
| Objective response rate (ORR) on tumor assessments | Through the study completion, an average of 2 years |
| ADA and NAb incidence | Through the study completion, an average of 2 years |
| Mean and median Maximum concentration (Cmax) of BT02 following first dose and repeated administration at each dose level | Through study completion, an average of 2 years |
| Progression-free survival (PFS) on tumor assessments | Through the study completion，an average of 2 years |
| Overall survival (OS) on tumor assessments | Through the study completion, an average of 2 years |
| Duration of response (DoR) on tumor assessments | Through the study completion, an average of 2 years |
Contacts
Primary ContactClinical development director
Outcome results
None listed